FDA warned Flax & More Corporation that its dietary supplements were made under conditions that failed required manufacturing quality rules.
What happened
FDA inspected the facility from October 21 through 29, 2025, and issued a Form FDA 483 listing inspection observations at the close. The inspection found violations of current good manufacturing practice (CGMP), the required quality rules for dietary supplement manufacturing; FDA calls the products adulterated, meaning they were prepared under conditions that do not meet CGMP requirements. FDA found dietary supplement residue in equipment seams and missing or incomplete product specifications and master manufacturing records, and it found the firm’s November 20, 2025 response insufficient.
What FDA found
FDA found that equipment seams were not maintained to prevent residue buildup; a hopper had dietary supplement residue in its seams, and shared equipment was used for products with and without wheat bran.
21 CFR 111.27(a)(4)The firm did not establish finished-product specifications for identity, purity, strength, and composition of its dietary supplements.
21 CFR 111.70(e)The master manufacturing record for a product lacked a theoretical yield statement, including maximum and minimum yield limits for deviation review, and lacked sampling procedures or a cross-reference to test procedures.
21 CFR 111.210(f); 21 CFR 111.210(h)(2)
What FDA wants
FDA asks the firm to notify it in writing within 15 working days of receipt of the letter of specific steps taken to address the violations, with explanations, documentation, and steps to prevent recurrence. If corrective actions cannot be completed in that time, the firm must state why and when it will finish.
Who should pay attention
- dietary supplement brands that use contract manufacturers
- companies making allergen-free products on shared equipment
- quality teams responsible for cleaning and manufacturing records
This is a summary. Read the original letter on fda.gov.